A donor-dependent fraction of human Lp(a) lacks lysine-binding capability, failing to inhibit plasminogen activation or bind fibrinogen, which highlights functional heterogeneity that may affect its atherothrombotic risk profile.
Answers are grounded in this paper and cite their sources.
Lp(a) functional heterogeneity may modulate atherothrombotic risk; leaves open isoform-specific effects on human cardiovascular outcomes.
Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for atherosclerosis. Lp(a) consists of a LDL-like moiety with an additional glycoprotein, apo(a), linked to apolipoprotein B-100. Apo(a) has a high homology with plasminogen (Pg). In vivo, Pg is activated on a fibrin surface by tissue Pg activator (tPA). We prepared Lp(a) from plasma by sequential ultracentrifugation followed by lysine-sepharose affinity chromatography. We found that a changing (donor dependent) fraction of the Lp(a) did not bind to lysine-sepharose. This fraction, designated Lp(a)lys-, was further purified using gel filtration. Bound Lp(a) [Lp(a)lys+] was eluted with 0.2 M EACA. Apo(a) isoforms in both fractions were identical. In contrast Lp(a)lys+ inhibited Pg activation by tPA in vitro (IC50% 20 mg/l), whereas Lp(a)lys- did not. In addition Lp(a)lys- did not bind to CNBr-digested fibrinogen whereas Lp(a)lys+ did (Kd, app = 0.2 nM). Therefore we conclude that a changing donor dependent fraction of human plasma Lp(a) does not inhibit Pg activation in vitro and does not bind to CNBr-digested fibrinogen.
No takes yet. Share an insight, caveat, or question.
Leerink et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: